Cargando…
Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
INTRODUCTION: Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically rele...
Autores principales: | Abinusawa, Adeyinka, Tenjarla, Srini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4449368/ https://www.ncbi.nlm.nih.gov/pubmed/25951927 http://dx.doi.org/10.1007/s12325-015-0206-4 |
Ejemplares similares
-
Dissolution of Commercially Available Mesalamine Formulations at Various pH Levels
por: Tenjarla, Srini
Publicado: (2015) -
Controlled Release of 5-Aminosalicylic Acid (5-ASA) from New Biodegradable Polyurethanes
por: Kenawy, El-Refaie, et al.
Publicado: (2010) -
Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications
por: Richter, James M., et al.
Publicado: (2016) -
Mucosal concentrations of N‐acetyl‐5‐aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine
por: Fukuda, Tomohiro, et al.
Publicado: (2020) -
Pharmacokinetics in Wistar Rats of 5-[(4-Carboxybutanoyl)Amino]-2-Hydroxybenzoic Acid: A Novel Synthetic Derivative of 5-Aminosalicylic Acid (5-ASA) with Possible Anti-Inflammatory Activity
por: Romero-Castro, Aurelio, et al.
Publicado: (2016)